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Lactobacillus helveticus in combination with Flavourzyme® was used for producing ACE-I 27 
peptides from reconstituted skim milk and whey protein concentrate. Fermentation of skim 28 
milk by L. helveticus in combination with Flavourzyme® resulted in >80% ACE-I after 8 h. 29 
These conditions can be used for developing a functional drink with antihypertensive activity. 30 
 31 
Abstract 32 
Angiotensin converting enzyme inhibitory (ACE-I) activity as affected by Lactobacillus 33 
helveticus strains (881315, 881188, 880474 and 880953), and supplementation with a 34 
proteolytic enzyme was studied. Reconstituted skim milk (12 % RSM) or whey protein 35 
concentrate (4 % WPC), with and without Flavourzyme® (0.14 % w/w), were fermented with 36 
4 different L. helveticus strains at 37 °C for 0, 4, 8, 12 hours. Proteolytic and in vitro ACE-I 37 
activities, and growth were significantly affected (P < 0.05) by strains, media and with 38 
enzyme supplementation. RSM supported higher growth and produced higher proteolysis and 39 
ACE-I than that WPC without enzyme supplementation. The strains L. helveticus 881315 and 40 
881188 were able to increase ACE-I to > 80 % after 8 h of fermentation when combined with 41 
Flavourzyme® in RSM compared to the same strains without enzyme supplementation. 42 
Supplementation of media by Flavourzyme® was beneficial in increasing ACE-I peptides in 43 
both media. The best media to release more ACE-I peptides was RSM with enzyme 44 
supplementation. The L. helveticus 881315 outperformed all strains as indicated by highest 45 
proteolytic and ACE-I activities.  46 
  47 
Keywords: ACE Inhibition, Flavourzyme, Lactobacillus helveticus, skim milk   48 
 49 
  50 
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Introduction 51 
Hypertension is considered a risk factor for coronary heart disease such as, myocardial 52 
infarction and stroke (FitzGerald and others 2004). According to the World Health 53 
Organization nearly one billion people worldwide suffer from hypertension (World Health 54 
Organization 2013). Hypertension is usually controlled by a number of drugs, the most 55 
common being synthetic angiotensin converting enzyme inhibitory (ACE-I) drugs such as 56 
captopril and enalapril (Hansson and others 1999; Turner and Hooper 2002). ACE-I drugs 57 
decrease active angiotensin-II production from inactive angiotensin-I (Erdos 1975; 58 
FitzGerald and others 2004). Angiotensin-II receptor antagonists are agents used to modify 59 
the renin-angiotensin-aldosterone system through blocking angiotensin receptors, resulting in 60 
a decrease in blood pressure (Miura and others 2011). Also, ACE-I is a single polypeptide 61 
chain, composed of 2 separate and independent catalytic domains. Each domain contains the 62 
zinc-binding; these domains, called N- and C-domains have a high conservation of sequence 63 
and exon structure (Soubrier and others 1988). N- and C-terminal domains of ACE are 64 
similar in amino acid sequence, although both domains are sensitive to chloride. The C-65 
domain requires a much higher chloride concentration for optimal activity than that the N-66 
domain. The 2 catalytic domains exhibit different sensitivities to individual ACE inhibitors 67 
(Michaud and others 1997). Long term use of synthetic ACE-I drugs however, may result in 68 
side effects such as, cough, skin rash or development of impaired renal function (Sesoko and 69 
Kaneko 1985; Coulter and Edwards 1987). Peptides such as Val-Pro-Pro and Ile-Pro-Pro 70 
derived from milk proteins (FitzGerald and Meisel 2000; Nielsen and others 2009; Pihlanto 71 
and others 2010; Pihlanto-Leppälä 2000; Pan and others 2005; Phelan and Kerins 2011; Tsai 72 
and others 2008) have been identified to have similar effects of ACE-I action opening 73 
possibilities of replacing or complementing synthetic drugs (FitzGerald and Meisel 2000; Pan 74 
and others 2005; Tsai and others 2008; Nielsen and others 2009; Yamaguchi and others 2009; 75 
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Pihlanto and others 2010; Phelan and Kerins 2011). Lactic acid bacteria (LAB) used to 76 
produce fermented dairy products (i.e. yoghurt, fermented milk, cheeses) have shown varied 77 
but significant ACE-I activities during fermentation as reported in several studies (Korhonen 78 
2009; Phelan and Kerins 2011; Korhonen and Pihlanto 2003, 2006, 2007; Hernández-79 
Ledesma and others 2011). The use of specific LAB or proteases in producing ACE-I 80 
peptides from various milk media (yoghurt, cheese, sour milk) have been reported (van der 81 
Ven and others 2002; Donkor and others 2005; Pan and others 2005; Kilpi and others 2007; 82 
Meena and others 2008; Tsai and others 2008; Korhonen 2009; Hamme and others 2009; 83 
Ramchandran and Shah 2010, 2011; Tellez and others 2011; Chaves-López and others 2012; 84 
García-Tejedor and others 2013).The proteolytic activity and bioactivity of peptides is 85 
influenced by a number of factors, such as, type of growth media, fermentation time, 86 
temperature and pH type of LAB species and strain type used for fermentation (Ramesh and 87 
others 2012). Several bioactive peptides which have ACE-I activity have been derived from 88 
hydrolysis of proteins using skim milk and whey protein concentrate (Madureira and others 89 
2010; Donkor and others 2007b). Such peptides have clinically documented effects in the 90 
reduction of hypertension in humans (Aihara and others 2005). 91 
Lactobacillus helveticus (L. helveticus) is homo fermentative thermophilic lactic acid bacteria 92 
and known to possess strong proteolytic activity and is used in the production of Swiss 93 
cheese and fermented milk beverages (Kenny and others 2003; Griffiths & Tellez 2013). Due 94 
to its high proteolytic activity, L. helveticus is more effective than that other LAB such as L. 95 
delbrueckii sp. bulgaricus and L. acidophilus in the production of ACE-I peptides (Korhonen 96 
and Pihlanto 2006). Several studies have reported the use of L. helveticus for production of 97 
ACE-I peptides and L. helveticus strains are specifically used for cheese production such as 98 
Swiss cheese (Maeno and others 1996; Leclerc and others 2002; Kilpi and others 2007; 99 
Nielsen and others 2009; Sun and others 2009; Pan and Guo 2010a; Otte and others 2011; 100 
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Singh and others 2011; Lim and others 2011; Unal and Akalin 2012; Grifiths and Tellez 101 
2013). The effect of temperature, fermentation time and initial pH of fermented milk by L. 102 
helveticus has been reported for sour milk production (Pan and Guo 2010b). Peptides can be 103 
derived from enzymatic hydrolysis and considered to be safer (Pihlanto-Leppälä, 2000). 104 
Moreover, enzymatic hydrolysates exert a variety of additional physiological properties such 105 
as antioxidant and antimicrobial (Pihlanto-Leppälä 2000). Some of these peptides are present 106 
within the parent protein structure and could be released through proteolysis (FitzGerald and 107 
Murray 2006). However, proteinases such as (Alcalase, chymotrypsin pancreatin, pepsin, 108 
enzymes from bacterial and fungal) have been utilized to generate bioactive peptides 109 
(Pihlanto-Leppälä, 2000). In this study, we chose Flavourzyme® individually or in 110 
combination, to increase the production of peptides from milk proteins hydrolyses. Since 111 
there are no published reports on the production of ACE-I peptides from milk employing 112 
proteases and LAB, we screened L. helveticus strains for production of ACE-I peptides from 113 
12 % reconstituted skim milk (RSM) and 4 % whey protein concentrate (WPC) with or 114 
without protease (Flavourzyme®) supplementation by measuring the bacterial growth, 115 
proteolytic activity and in vitro ACE-I activity. Therefore, the present study was performed to 116 
evaluate the hypothesis that combination of Flavourzyme® with L. helveticus significantly 117 
increase ACE-I % in both media. 118 
 119 
 Material and methods 120 
Material and chemical  121 
  122 
 Four strains of L. helveticus  881315, 881188, 880474 and 880953 were obtained from 123 
(Dairy Innovation Australia Ltd, Werribee, VIC, Australia) and stored in 40 % glycerol de 124 
Man, Rogosa, and Sharpe (MRS) broth (Oxoid, Ltd., West Heidelberg, VIC, Australia) at 125 
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−80 °C. Flavourzyme®   was 1000 L (EC 3.4.11.1, an amino peptidase with an activity of 126 
1000  Leucine Amino-peptidase (LAPU g-1) as quoted by Novozymes Australia., NSW, 127 
Australia). RSM was purchased from (Murray Goulburn Co-operative Co. Ltd., VIC. 128 
Australia). WPC was obtained from (United Milk Tasmania Ltd., TAS Australia). MRS agar 129 
was obtained from (Merck Pty. Ltd., VIC Australia). Anaerobic kit was purchased from (An 130 
aero Gen™, Oxoid. Zweigniederlassung, Austria). The O-phthaldialdehyde (OPA) obtained 131 
from (Sigma Aldrich., NSW Australia).  Disodium tetra-borate was obtained from (Merck 132 
Pty. Ltd., VIC Australia). Sodium dodecyl sulphate (SDS) was from (Merck Pty. Ltd). β-133 
mercaptoethanol (Sigma Aldrich). Trichloroacetic acid (TCA) was purchased from (Sigma 134 
Aldrich). Advantech # 231 filter paper was from (Advantech Australia., NSW Australia). The 135 
ACE enzyme and Hippuryl-histidyl-leucine (HHL) were obtained from (Sigma, St. Louis, 136 
MO, USA). C-18 column Gemini® C18 110 Å (100 mm x 4.6 mm, 5 µm) was from 137 
(Phenomenex, Pty Ltd., NSW Australia). Acetonitrile was from (Merck Pty. Ltd., VIC 138 
Australia). RP- HPLC was from (Varian Analytical Instruments., CA USA).  C-18 139 
monomeric column (5 μm, 300 Å, 250 mm x 4.6 mm) was from (Grace Vydac, Hesperia CA, 140 
USA). Freeze-dried was (Air vac Engineering Private Ltd., VIC, Australia, model FD-300). 141 
For activation, an aliquot (100 µL) of each strain was individually transferred into MRS broth 142 
and incubated at 37 °C for 24 hours (h). Weekly subculturing of bacteria into MRS broth was 143 
performed to maintain the bacterial activity. Prior to each experiment, bacteria were 144 
subcultured 3 times and fermented for 12 h in 12 % RSM or 14 % WPC.    145 
 146 
Media preparation and bacteria propagation RSM (12 %) and WPC (4 %) were prepared 147 
by dissolving appropriate quantities of skim milk powder (52 % lactose, 37 % protein, 8.6 % 148 
ash and 1.2 % fat) and WPC (47.5 % lactose, 35 % protein, 9 % ash, 2.5 % fat) in distilled 149 
water . Both media were heated to 90 °C for 30 minutes (min). The prepared media, with or 150 
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without 0.14 % (w/w) Flavourzyme®1000 L were inoculated with L. helveticus strains and 151 
fermented at 37 °C for 4 h, 8 h and 12 h. Sixteen different combinations of bacterial strains, 152 
Flavourzyme® (0.14%) and growth media  (12 % RSM or 4% WPC) were used (Table 1). 153 
Samples were collected and stored at -20 °C for analysis of bacterial growth, proteolytic 154 
activity and ACE-I activities and peptide profiling by Reverse phase - High-performance 155 
liquid chromatography (RP-HPLC).  156 
 157 
Methods 158 
 159 
Measurement of bacterial growth  160 
Growth was assessed every 4 h up to 12 h during fermentation by pour plate method using 161 
MRS agar  following serial dilutions with 0.1 % peptone. The plates were incubated 162 
anaerobically at 37 °C for 48 h using anaerobic jars with anaerobic kit. Plates having 25 - 250 163 
colonies were counted and the growth was expressed as logarithm of colony forming unit 164 
(cfu) per mL-1 of sample. 165 
 166 
Determination of proteolytic activity 167 
The O-phthaldialdehyde (OPA)   reagent was prepared by mixing 25 mL of 100 mM 168 
disodium tetra-borate, 2.5 mL of 20 % (w/w) sodium dodecyl sulfate (SDS), 1 mL methanol 169 
containing 40 mg of OPA and 100 µL of β-mercaptoethanol . The final volume was made to 170 
50 mL with Deionized water. Briefly, the sample (3 mL) was mixed with equal volume of 1 171 
% trichloroacetic acid (TCA)  followed by filtration using Advantech # 231 filter paper .  172 
Filtrate (150 µL) was placed into 4 mL cuvette and mixed with 3 mL OPA reagent, and 173 
absorbance measured at 340 nm using UV-VIS spectrophotometer (LKB NOVASPEC II 174 
Pharmacia, LKB Bio- Chrom, UK) after allowing 2 min of reaction time at room temperature 175 
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as a measure of proteolysis. The degree of proteolysis was determined as the difference 176 
between proteolytic activities in fermented media to that of unfermented media (Donkor and 177 
others 2007b). 178 
 179 
Determination of ACE-Inhibitory activity  180 
ACE-I activity was determined according to a Donkor and others (2007a). Briefly,  fermented 181 
media (WPC or RSM) (10 mL) was centrifuged at 4000 x g at 4 °C for 30 min and the 182 
supernatant was freeze-dried for 72 h. The freeze-dried powder (40 mg) was dissolved in 2 183 
mL Tris buffer (50 mM, pH 8.3) containing 300 mM sodium chloride. ACE enzyme and 184 
Hippuryl-histidyl-leucine (HHL)  were prepared in Tris buffer. Fifty µL of 3.0 mM HHL, 50 185 
µL of 1.25 MU ACE enzyme (from rabbit lung), and 50 µL of experimental samples were 186 
placed in a glass tube and incubated for 1 h at 37 °C ensuring mixing for the first 30 min. 187 
Glacial acetic acid (150 µL) was added to stop the reaction. The reaction mixture was stored 188 
at -20 °C before further analysis of released hippuric acid (HA) by HPLC. An external 189 
standard curve of hippuric acid was prepared to quantify the resultant hippuric acid in 190 
fermented samples. An aliquot (20 µL) of the mixture was injected into Gemini® C18 110 Å 191 
(100 mm x 4.6 mm, 5 µm) using Varian HPLC equipped with an auto sampler. The 192 
separation was conducted at room temperature (~22 °C) at a mobile phase flow rate of 0.6 193 
mL min-1. The mobile phase consisting of 12.5 % (v/v) acetonitrile in Deionized -water, and 194 
pH was adjusted to 3.0 using glacial acetic acid. Ultraviolet-visible detector was set at 228 195 
nm. The % ACE-I was calculated as follows: 196 
ACEI % = HA (control) − HA (sample)HA (control)  × 100 197 
 198 
 199 
 200 
9 
 
 201 
 202 
RP-HPLC analysis of water-soluble peptides extract 203 
Reconstituted skim milk fermented with the highest ACE-I activity of strains; L. helveticus 204 
881188 and 881315 (with or without combination of Flavourzyme®) were collected after 12 h 205 
of fermentation (pH 4.6). From this, 50 mL sample was centrifuged at 4000 x g at 4 °C for 30 206 
min to separate proteins. The supernatant containing soluble peptides was freeze-dried  for 72 207 
h.  The powder (40 mg) was dissolved in 0.1 % trifluoroacetic acid (TFA). Water soluble 208 
peptides were profiled by a RP- HPLC  using C-18 monomeric column (5 μm, 300 Å, 250 209 
mm x 4.6 mm) (Donkor and others 2007a). 210 
 211 
Statistical analysis 212 
All results are expressed as mean values of 3 replicates with standard deviation of the mean. 213 
One way ANOVA was performed to differentiate the significant differences in the treatments 214 
which were strains, growth media, presence or absence of Flavourzyme®, and fermentation 215 
time. The level of significance was tested at P < 0.05. Fisher`s (least significant difference; 216 
LSD) test was used to investigate significant differences among the treatment means. 217 
Correlation analysis was carried out between variables for same bacteria strain, growth media 218 
and presence or absence of Flavourzyme®. The degree of correlation between these variables 219 
was expressed as Pearson coefficient (r) and corresponding P values. All statistical analyses 220 
were carried out using SAS Version 9.0 software (SAS Institute Inc., Cary, NC, USA) 221 
 222 
Results and discussion 223 
Preferential growth of L. helveticus in RSM media with Flavourzyme® compared to 224 
WPC  225 
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Figure 1 shows the microbial growth and pH in RSM and WPC during fermentation with L. 226 
helveticus. All L. helveticus strains were able to grow in both media (Figure 1). Analysis of 227 
variance showed that bacterial growth was significantly (P < 0.05) affected by media, media 228 
supplementation with protease (Flavourzyme®), fermentation time and strain type. Higher 229 
growth was significantly noted (P < 0.05) in RSM. This may be attributed to superior nutrient 230 
profile of RSM  (Kilpi and others 2007; Leclerc and others 2002) and higher specificity to 231 
caseins than whey proteins. Media supplemented with Flavourzyme® led to increase growth 232 
owing to enhanced number of released more peptides and amino acids required for bacterial 233 
growth in log and early stationary phases, associated to no supplementation in both media 234 
types (Kenny and others 2003). While L. helveticus 881315 showed the least growth (0.6) 235 
Log10 cfu ml-1, the L. helveticus 881188 showed highest growth (2) Log10 cfu ml-1 at 12 h 236 
compared to other strains in RSM containing Flavourzyme® for the entire duration of 237 
fermentation. L. helveticus strains 880474 and 880953 also showed the higher growth 238 
compared to 881315 in RSM. It appears that Flavourzyme® supplementation prolonged the 239 
log phase in 881188 whereas 880474 and 880953 strains went into a decline phase after 8 h. 240 
In general, WPC showed a weak growth for all strains without the combination of 241 
Flavourzyme® compared to same strains in combination with Flavourzyme® (Figure 1C and 242 
D). However, growth for all strains in WPC with Flavourzyme® were increased significantly 243 
at 8 h and declined after 8 h of fermentation at pH (3.4) possibly, due to the effect of pH and 244 
heat treatment on WPC’s nutrient contents as previously reported (Zisu and Shah 2003 ; 245 
Dissanayake and others 2013). Furthermore the decrease in bacterial growth observed after 8 246 
h of fermentation can be attributed to the production of lactic acid in media by growing lactic 247 
acid bacteria which can inhibit bacterial growth at low pH concentrations. Similar growth 248 
characteristics were noted with LAB at different temperatures and fermentation time in RSM 249 
using L. sakei CTCstrains which showed inhibition of L. sakei growth due to lactic acid 250 
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production (Leroy and de Vuyst, 2001).However, different results were noted that L. 251 
helveticus strain’s cell counts were increased during fermentation 12 % RSM from (0 – 9) h 252 
followed by a slight decrease in viable counts until (24 h) of the fermentation (Leclerc and 253 
others 2002). It is clear that the difference observed in bacterial growth in both media could 254 
be related to the different nature of proteins present (Leclerc and others 2002). 255 
 256 
Proteolytic activity is higher in RSM media with Flavourzyme® 257 
Milk proteins were hydrolysed by L. helveticus strains (881315, 881188, 880474 and 258 
880953), resulting in an increase in the amount of free NH3 groups as quantified by the OPA 259 
method (Figure 2). The proteolytic activity of L. helveticus strains grown in RSM or WPC 260 
with or without Flavourzyme® supplementation at 37 °C for 0-12 h increased with 261 
fermentation time (Figure 2). All strains preferred RSM over WPC with or without 262 
supplementation with Flavourzyme® as indicated by higher proteolysis. The activity 263 
remained significantly lower (≤ 0.5) in WPC compared to RSM (> 0.78), indicating that 264 
proteins of RSM particularly, casein were the preferred substrate by enzymes of L. helveticus 265 
strains. This correlated to a similar trend in the growth pattern (Figure 1). The order of 266 
proteolytic activity of L. helveticus strains in RSM was 881315 > 881188 > 880474 > 267 
880953. Supplementation of RSM with Flavourzyme® increased the proteolytic activity of all 268 
strains significantly (P < 0.05), reaching a maximum absorbance > 1.8 in 12 h by L. 269 
helveticus 881315, 880474 and 881188 (Figure 2). Interestingly, the proteolytic activity of 270 
strain 881315 was high during 12 h (Figure 2). However,  the growth was weak in both media 271 
(Figure 1). The activity in RSM with Flavourzyme® was approximately higher by 45-60 % 272 
than that without Flavourzyme® even after 4 h of fermentation and was sustained over the 12 273 
h duration of fermentation. However, except for L. helveticus 880953, the response to 274 
Flavourzyme® in increasing proteolysis was similar after 8 h of fermentation. Flavourzyme® 275 
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appears to have hydrolysed large proteins present in RSM to intermediate peptides, which 276 
were used by L. helveticus to produce small peptides and free amino acids (Leclerc and others 277 
2002). Co-fermentation of RSM with Flavourzyme® supplementation with L. helveticus 278 
strains reduced the time required for a given degree of proteolysis. These results suggest that 279 
proteolysis were enhanced in the higher protein content was in media supplemented with 280 
Flavourzyme® and that casein was a better substrate than that whey proteins for L. helveticus 281 
strains. Similar results have been noted that proteolytic activity was enhanced in the higher 282 
protein content medium and that casein fraction was a better substrate than whey proteins for 283 
the extracellular proteinases of lactic acid bacteria (Leclerc and others 2002).  In addition, the 284 
amount of free NH3 groups in the media increased sharply until 12 h except for media 285 
without Flavourzyme® for which a slightly slower than that sharply increase was observed 286 
after 8 h (Figure 2). The different proteolytic activities between strains could also be 287 
explained by the higher proteolysis noted by Matar and others (1996) for L. helveticus L89, 288 
compared to those measured for strains 881315, 881188, 880474, and 880953 in this study. 289 
 290 
ACE-Inhibitory activity is influenced by strain type, media and Flavourzyme® 291 
combination 292 
The amount and type of peptides produced during hydrolysis of proteins present in RSM or 293 
WPC influenced ACE-I activity which was measured using an ACE-I method according to 294 
Donkor et al., (2007a). The % of ACE-I activity of L. helveticus strains (881315, 881188, 295 
880474 and 880953)  in RSM or WPC with or without Flavourzyme® at 37 °C for 12 h are 296 
presented in Figure 2.  Flavourzyme® alone was used as a control. ACE-I activity for all 297 
strains in both media increased significantly during fermentation period (P < 0.05). However, 298 
differences existed between strains and media used when compared at the same time of 299 
fermentation. Media type, strains, supplementation of Flavourzyme® and fermentation time 300 
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had significant (P < 0.05) effects on ACE-I activity. As with proteolytic activity, ACE-I 301 
activity increased as fermentation time increased for all strains. Supplementation of RSM 302 
with Flavourzyme® significantly (P < 0.05) increased ACE-I activity of L. helveticus strains. 303 
Except for L. helveticus 880474, ACE-I increased from 40-60 % to ≥ 85 % in RSM with 304 
Flavourzyme® supplementation after 8 h of fermentation. The inhibition increased during 305 
fermentation when L. helveticus 881315 and 881188 were used from 10 % to 89.82 % and 306 
from 5 % to 85 % in RSM with supplementation, respectively (Figure 2B). While the same 307 
strains in WPC with Flavourzyme® supplementation, the ACE-I % increased from 10 % to 65 308 
% and 5 % to 60 % during 12 h, respectively (Figure 2D). Since both of these strains 309 
demonstrated high proteolysis, co-fermentation with enzyme appeared to have produced 310 
higher amounts of ACE-I peptides as evident in increased number of peaks (Figure 3).  The 311 
inhibitory activity remained high at 12 h for all strains except L. helveticus 880474 which 312 
showed a significant drop in ACE-I after 4 h of fermentation. There was no significant 313 
difference (P < 0.05) in ACE-I between hydrolysates produced from WPC with or without 314 
Flavourzyme® at 4 h fermentation. Thereafter, ACE-I increased differentially among the 315 
strains and a maximum of 89.82 % was observed for L. helveticus 881315 with 316 
Flavourzyme® in RSM at 12 h. However, the growth Log10 of same strain was weak during 317 
12 h (Figure 1), that means this strain has high proteolytic activity. This supported by study 318 
reported that “the declining number of live bacteria alterations in ACE-inhibitory activity in 319 
the cultures of peptidase-negative mutants could be detected during the course of cultivation, 320 
which indicates that the proteolytic enzymes released from cells of L. helveticus play an 321 
important role in the conversion of bioactive peptides” (Kilpi and others 2007).   Data also 322 
suggest a delayed effect with addition of Flavourzyme® in WPC. The increase in ACE-I was 323 
significantly (P < 0.05) higher in RSM compared to WPC due to the addition of 324 
Flavourzyme® and may be due to the sensitivity of whey protein to heat treatments (Banks 325 
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and others 1995; Patel and Creamer 2008). The ACE-I activity differed significantly between 326 
strains.  L. helveticus 881315 and 881188 showed higher ACE-I activity compared to other 327 
strains in RSM (Figure 2). This implies that Flavourzyme® enhanced the production of ACE-328 
I peptides as previously reported and supported by the proteolysis pattern observed (Tsai and 329 
others 2008). Since ACE-I almost doubled in the first 8 h of fermentation, Flavourzyme® 330 
supplementation can be used to reduce time of hydrolysis required for production of ACE-I 331 
peptides.  The differences observed between RSM and WPC may be attributed to differences 332 
in the type of proteins present and therefore the variety of peptides present in the hydrolysates 333 
(Matar and others 1996; Pan and Guo 2010b). Preference to casein by proteinases has been 334 
reported (Lim and others 2011; Cheison and others 2007; Matar and Goulet 1996). It was 335 
possible to achieve maximum ACE-I of 60 % and 70 % without supplementation of RSM or 336 
WPC by L. helveticus strain 881315 after 8 h of fermentation, respectively. On the other 337 
hand, with supplementation of RSM, ACE-I % was achieved to 89.82 %. However, 338 
fermentation process using Flavourzyme® alone as control have a small  effective in 339 
increasing ACE-I activity as indicated by the low ACE-I (20 - 38%) for hydrolysates 340 
produced. 341 
RP-HPLC analysis of water-soluble peptide extracts suggests that L. helveticus 881315 342 
with Flavourzyme® is most optimal 343 
The profiles of water-soluble peptide extracts of 12 h fermented skim milk hydrolysates by 344 
best performer strains (as measured by proteolytic and ACE-I activities) L. helveticus 345 
(881315 and 881188) with or without supplementation of Flavourzyme® are shown in Figure 346 
3. The RP-HPLC elution profile of the hydrolysates was based on the hydrophobicity of the 347 
peptides. In the control unfermented RSM only one peak appeared at 10 min (not shown) 348 
only. The chromatograms (Figure 3A, 3C) show that 881315 and 881188 strains without 349 
supplementation hydrolysed proteins resulting in peptides in the retention time range of 10-40 350 
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min and 10-45 min by strains respectively. Supplement with Flavourzyme® (Figure 3B, 3D) 351 
generally aided both strains to increase proteolysis as evident by the presence of more 352 
peptides appearing in the range of 10-65 min (881315) and 10-45 min (881188).  Strain 353 
881315 combined with Flavourzyme® was most optimal in terms of providing peptides by 354 
facilitating proteolysis of caseins present in RSM. This corroborated to the high ACE-I 355 
activity (Figure 2). However, supplementation was more beneficial to strain 881315 than that   356 
881188.    357 
 358 
 359 
 360 
Correlation between proteolytic activity, ACE-Inhibition and bacteria growth  361 
The correlation between proteolytic activity and anti-hypertensive properties expressed as 362 
ACE-I and bacterial growth for the same bacterial strain, growth media and with or without 363 
Flavourzyme® are presented in (Tables 2 and 3) for RSM and WPC respectively. A 364 
significant correlation in growth with all measurements for each strain in RSM was evident 365 
for except L. helveticus 880953 which did not grow well in both media (P < 0.05). Even 366 
stronger correlations between the same measurements were observed for RSM supplemented 367 
with Flavourzyme® (Table 2). This suggests that Flavourzyme® enhanced the proteolytic and 368 
ACE-I activities of L. helveticus in RSM. ACE-I activity positively and strongly correlated 369 
with proteolytic activity for each strain, both with or without Flavourzyme® (P < 0.05) (Table 370 
2) implying that increased proteolytic activity increased the production of ACE-I peptides. 371 
ACE-I activity had positive and strong correlation with bacterial growth (cfu) in RSM (with 372 
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or without Flavourzyme®) for all strains except L. helveticus 880953. This suggests that 373 
proteolytic and ACE-I activities were growth dependent. Similar trend was observed in WPC  374 
 375 
 376 
 377 
Conclusion 378 
Production of ACE-I peptides by L. helveticus varied between the strains due to differences 379 
in proteolytic activity.  Casein rich RSM supported higher growth, higher proteolytic activity 380 
and produced higher ACE-I activities by all L. helveticus strains. Therefore, RSM is superior 381 
to WPC as a medium for production of ACE-I peptides irrespective of supplementation with 382 
protease, which generally increased hydrolysis of proteins to produce more ACE-I peptides. 383 
Beneficial effects of protease supplementation were more pronounced in the first 8 h of 384 
fermentation and also sustained thereafter. However, L. helveticus 881315 showed the lowest 385 
growth. The highest ACE-I activity was observed in 12% RSM supplemented with 386 
Flavourzyme® and up to 12 h fermentation by L. helveticus 881315 and 881188 at 37 °C, 387 
respectively. These conditions will aid in the production of a functional fermented drink with 388 
high ACE-I activity.  389 
 390 
 391 
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Table 1- Experimental design to analyse and measure the pH, growth, proteolytic activity 575 
and % of ACE-inhibitory activities during (0, 4, 8 and 12 h) fermentation of L. helveticus 576 
strains in 12 % RSM or 4 % WPC and with or without combination of Flavourzyme® 577 
 578 
 579 
 580 
 581 
 582 
 583 
 584 
 585 
 586 
 587 
 588 
 589 
 590 
 591 
 592 
 593 
Media 
used 
 L. helveticus strains  used 
without combination 
Combination of L. helveticus 
strains with Flavourzyme® (1 % 
v/v each) 
RSM  881315 881315+Flavourzyme® 
 881188 881188+Flavourzyme® 
  880474 880474+Flavourzyme® 
 
control 
880953 
 
Flavourzyme® 
880953+Flavourzyme® 
 
WPC  881315 881315+Flavourzyme® 
 881188 881188+Flavourzyme® 
  880474 880474+Flavourzyme® 
 
control 
880953 
 
Flavourzyme® 
880953+Flavourzyme® 
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Table 2- Pearson coefficient correlations (r), proteolytic activity (OPA), ACE-inhibitory activity (ACE) and bacterial growth (CFU) for strain, L. 594 
helveticus 881315, L. helveticus 881188, L. helveticus 880474 and L. helveticus 880953 grown in 12 % RSM at 37 °C for 12 h with or without 595 
Flavourzyme® combination 596 
L. helveticus strains Variables Without Flavourzyme
® With Flavourzyme® 
 OPA ACE CFU  OPA ACE CFU 
881315 OPA  1.000 0.988** 0.918**  1.000 0.979** 0.946** 
 ACE   1.000 0.945**   1.000 0.864** 
 CFU    1.000    1.000 
          
881188 OPA  1.000 0.991* 0.874*  1.000 0.966* 0.852* 
 ACE   1.000 0.882*   1.000 0.694** 
 CFU    1.000    1.000 
          
880474 OPA  1.000 0.962** 0.805*  1.000 0.978* 0.835* 
 ACE   1.000 0.825*   1.000 0.928* 
 CFU    1.000    1.000 
          
880953 OPA  1.000 0.989* 0.690**  1.000 0.891* 0.863* 
 ACE   1.000 0.588**   1.000 0.597* 
 CFU    1.000    1.000 
* P < 0.05, **P < 0.01. 597 
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Table 3- Pearson coefficient correlations (r), proteolytic activity (OPA), ACE-inhibitory activity (ACE) and bacterial growth (CFU) of, L. 598 
helveticus 881315, L. helveticus 881188, L. helveticus 880474 and L. helveticus 880953 grown in 4 % WPC at 37 °C for 12 h with or without 599 
Flavourzyme® combination 600 
L. helveticus strains Variables Without Flavourzyme® With Flavourzyme® 
 OPA ACE CFU  OPA ACE CFU 
881315 OPA  1.000 0.615* 0.713*  1.000* 0.530* 0.580* 
 ACE   1.000 0.927**   1.000 0.949** 
 CFU    1.000    1.000 
          
881188 OPA  1.000 0.946* 0.866*  1.000 0.626* 0.562* 
 ACE   1.000 0.947*   1.000 0.978** 
 CFU    1.000    1.000 
          
880474 OPA  1.000 0.615** 0.666*  1.000 0.867* 0.907* 
 ACE   1.000 0.894*   1.000 0.971* 
 CFU    1.000    1.000 
          
880953 OPA  1.000 0.716** 0.567*  1.000 0.686* 0.608* 
 ACE   1.000 0.827*   1.000 0.634** 
 CFU    1.000    1.000 
*P < 0.05, ** P < 0.01.601 
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605 
606 
    607 
 608 
 609 
 610 
Figure 1- Growth log10 (cfu) mL-1 (line) and pH (bars) of L. helveticus strains (611 
881315), ( 881188), (  880474) and ( 880953) at 37 °C for 12 h in 612 
(A) RSM, (B) RSM with Flavourzyme®, (C) WPC and (D) WPC with Flavourzyme® (Error 613 
bars depict standard error of the means) and lines above signify differences at (*) P < 0.05 614 
and (**) P < 0.01. 615 
 616 
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622 
 623 
Figure 2- Proteolytic activity at 320 nm (line) and ACE-I % (bars) of L. helveticus strains (624 
 881315), (  881188), (  880474), (  880953) and (625 
Flavourzyme® )as control at 37 °C for 12 h in (A) RSM, (B) RSM with Flavourzyme®, 626 
29 
 
(C) WPC and (D) WPC with Flavourzyme® (Error bars depict standard error of the means) 627 
lines above signify differences at (*) P < 0.05 and (**) P < 0.01. 628 
 629 
 630 
 631 
 632 
 633 
 634 
 635 
Figure 3- RP-HPLC peptide profile of water soluble extracts obtained from fermented skim 636 
milk made with a combination of L. helveticus strains and Flavourzyme® ; 881315(A), 637 
881315 with Flavourzyme® (B), 881188 (C) and 881188 with Flavourzyme® (D) after 12 h 638 
fermentation at 37 °C. 639 
30 
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